- Home
- SVM vs GERN Comparison
SVM vs GERN Comparison
Compare SVM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVM
- GERN
- Stock Information
- Founded
- SVM N/A
- GERN 1990
- Country
- SVM Canada
- GERN United States
- Employees
- SVM N/A
- GERN N/A
- Industry
- SVM Precious Metals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SVM Basic Materials
- GERN Health Care
- Exchange
- SVM Nasdaq
- GERN Nasdaq
- Market Cap
- SVM 769.7M
- GERN 840.7M
- IPO Year
- SVM N/A
- GERN 1996
- Fundamental
- Price
- SVM $3.85
- GERN $1.18
- Analyst Decision
- SVM Strong Buy
- GERN Buy
- Analyst Count
- SVM 1
- GERN 9
- Target Price
- SVM $5.10
- GERN $5.13
- AVG Volume (30 Days)
- SVM 5.7M
- GERN 11.2M
- Earning Date
- SVM 05-22-2025
- GERN 05-07-2025
- Dividend Yield
- SVM 0.65%
- GERN N/A
- EPS Growth
- SVM 104.66
- GERN N/A
- EPS
- SVM 0.36
- GERN N/A
- Revenue
- SVM $266,463,000.00
- GERN $116,293,000.00
- Revenue This Year
- SVM $38.08
- GERN $194.54
- Revenue Next Year
- SVM $1.71
- GERN $56.51
- P/E Ratio
- SVM $10.71
- GERN N/A
- Revenue Growth
- SVM 28.94
- GERN 22264.04
- 52 Week Low
- SVM $2.87
- GERN $1.17
- 52 Week High
- SVM $5.32
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- SVM 54.00
- GERN 32.46
- Support Level
- SVM $3.63
- GERN $1.34
- Resistance Level
- SVM $3.86
- GERN $1.44
- Average True Range (ATR)
- SVM 0.16
- GERN 0.10
- MACD
- SVM 0.01
- GERN 0.00
- Stochastic Oscillator
- SVM 86.90
- GERN 3.23
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral mining company. It acquires, explores, develops, and mines precious and base metal mineral properties at its producing mines and exploration and development projects in China. The group produces silver, gold, lead, and zinc. The company creates shareholder's value by focusing on generating free cash flow from long-life mines; organic growth through extensive drilling for discovery; equity investments in potential world-class opportunities; ongoing merger and acquisition efforts to unlock value; and long-term commitment to responsible mining and ESG. The Company's producing mines are located in China, and current exploration and development projects are located in China and Mexico.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.